Treatment of osteoarthritis in hypertensive patients

Bibliography

• Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362(9395):1527-35
   PubMed Web of Science ®Google Scholar
• MacMahon S, Peto R, Cutler J, Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for regression dilution bias. Lancet 1990;335:765-74
   PubMed Web of Science ®Google Scholar
• Collins R, Peto R, MacMahon S, Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335(8693):827-38
   Google Scholar
• Zhang W, Moskowitz RW, Nuki G, OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007;15(9):981-1000
   PubMedGoogle Scholar
• NICE clinical guideline 59. Osteoarthritis: the care and management of osteoarthritis in adults. www.nice.org.uk/CG059
   Google Scholar
• Aucott L, Poobalan A, Smith WC, Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension 2005;45(6):1035-41
   PubMedGoogle Scholar
• Evans JM, McMahon AD, McGilchrist MM, Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. BMJ 1995;311(6996):22-6
   Google Scholar
• Dominkus M, Nicolakis M, Kotz R, Comparison of tissue and plasma levels of ibuprofen after oral and topical administration. Arzneimittelforschung 1996;46(12):1138-43
   Google Scholar
• Kleinbloesem CH, Ouwerkerk M, Spitznagel W, Pharmacokinetics and bioavailability of percutaneous ibuprofen. Arzneimittelforschung 1995;45(10):1117-21
   Google Scholar
• Osteoarthritis: national clinical guideline for care and management in adults. Royal College of Physicians. London; 2008
   Google Scholar
• Pirmohamed M, James S, Meakin S, Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329(7456):15-19
   PubMedGoogle Scholar
• Antman EM, Bennett JS, Daugherty A, Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115(12):1634-42
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008;52(20):1628-36
   PubMed Web of Science ®Google Scholar
• Fosbol EL, Gislason GH, Jacobsen S, Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009;85(2):190-7
   PubMed Web of Science ®Google Scholar
• Chan FK, Abraham NS, Scheiman JM, Laine L. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008;103(11):2908-18
   Google Scholar
• MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361(9357):573-4
   Google Scholar
• Becker MC, Wang TH, Wisniewski L, Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J 2009;157(4):606-12
   Google Scholar
• Williams B, Poulter NR, Brown MJ, Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18(3):139-85
   Google Scholar
• Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005;46(3):500-7
   Google Scholar
• Kurth T, Hennekens CH, Sturmer T, Analgesic use and risk of subsequent hypertension in apparently healthy men. Arch Intern Med 2005;165(16):1903-9
   Google Scholar
• Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 2004;44(2):140-5
   Google Scholar
• Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987;32(1):1-12
   Google Scholar
• Gaziano JM. Nonnarcotic analgesics and hypertension. Am J Cardiol 2006;97(9A):10-16
   Google Scholar
• Colina-Chourio JA, Godoy-Godoy N, vila-Hernandez RM. Role of prostaglandins in hypertension. J Hum Hypertens 2000;14(Suppl 1):S16-S19
   Google Scholar
• Johnson AG, Nguyen TV, Owe-Young R, Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-1. J Hum Hypertens 1996;10(4):257-61
   Google Scholar
• Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 2003;63(6):525-34
   Google Scholar
• Wilson SL, Poulter NR. The effect of non-steroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J Hypertens 2006;24(8):1457-69
   Google Scholar
• Johnson AG, Seidemann P, Day RO. NSAID-related adverse drug interactions with clinical relevance. An update. Int J Clin Pharmacol Ther 1994;32(10):509-32
   Google Scholar
• Pimenta E, Gaddam KK, Oparil S, Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009;54(3):475-81
   Google Scholar
• Chalmers JP, West MJ, Wing LM, Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypertensive patients. Clin Exp Hypertens A 1984;6(6):1077-93
   Google Scholar
• Pavlicevic I, Kuzmanic M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol 2008;15(3):e372-82
   Google Scholar
• Curhan GC, Willett WC, Rosner B, Stampfer MJ. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 2002;162(19):2204-8
   Google Scholar
• Douglas L, Akil M. Sodium in soluble paracetamol may be linked to raised blood pressure. BMJ 2006;332(7550):1133
   Google Scholar
• Ubeda A, Llopico J, Sanchez MT. Blood pressure reduction in hypertensive patients after withdrawal of effervescent medication. Pharmacoepidemiol Drug Saf 2009;18(5):417-419
   Google Scholar
• McKenney JM, Wright JT Jr, Goodman RP, Effect of high-dose ibuprofen on 24-hour blood pressure in healthy women. Drug Intell Clin Pharm 1987;21(6):517-21
   Google Scholar
• Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153(4):477-84
   PubMedGoogle Scholar
• Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165(5):490-6
   PubMed Web of Science ®Google Scholar
• Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121(4):289-300
   Google Scholar
• Sowers JR, White WB, Pitt B, The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005;165(2):161-8
   Google Scholar
• Whelton A, Fort JG, Puma JA, Cyclooxygenase-2–specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8(2):85-95
   Google Scholar
• Aw TJ, Liew D, Tofler GH, Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels? J Hypertens 2006;24(10):1979-84
   Google Scholar
• MacDonald TM, Reginster JY, Littlejohn TW, Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. J Hypertens 2008;26(8):1695-702
   Google Scholar
• Whelton A, White WB, Bello AE, Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90(9):959-63
   Google Scholar
• Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens 2000;13(11):1161-7
   Google Scholar
• White WB, Kent J, Taylor A, Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002;39(4):929-34
   Google Scholar
• Mackenzie IS, Rutherford D, MacDonald TM. Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. Arthritis Res Ther 2008;10 (Suppl 2):S3
   Google Scholar
• Del SP, Sorrentino R, Pinto A. NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol Sci 1999;20(8):319-23
   Google Scholar
• Berndt G, Grosser N, Hoogstraate J, Schroder H. A common pathway of nitric oxide release from AZD3582 and glyceryl trinitrate. Eur J Pharm Sci 2004;21(2-3):331-5
   Google Scholar
• Wallace JL, Viappiani S, Bolla M. Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis. Trends Pharmacol Sci 2009;30(3):112-117
   PubMed Web of Science ®Google Scholar
• al-Swayeh OA, Clifford RH, Del SP, Moore PK. A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin. Br J Pharmacol 2000;129(2):343-50
   Google Scholar
• Cuzzolin L, Conforti A, Adami A, Anti-inflammatory potency and gastrointestinal toxicity of a new compound, nitronaproxen. Pharmacol Res 1995;31(1):61-5
   Google Scholar
• Fiorucci S, Antonelli E, Santucci L, Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology 1999;116(5):1089-106
   Google Scholar
• Michael HC, Sindet-Pederson S, Seymour RA, Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies. Clin Ther 2006;28(9):1279-95
   Google Scholar
• Schnitzer TJ, Kivitz AJ, Lipetz RS, Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee. Arthritis Rheum 2005;53(6):827-37
   Google Scholar
• Karlsson J, Pivodic A, Aguirre D, Schnitzer TJ. Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee. J Rheumatol 2009;36(6):1290-7
   Google Scholar
• Hawkey CJ, Jones JI, Atherton CT, Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 2003;52(11):1537-42
   Google Scholar
• Stokes GS, Bune AJ, Huon N, Barin ES. Long-term effectiveness of extended-release nitrate for the treatment of systolic hypertension. Hypertension 2005;45(3):380-4
   Google Scholar
• Haynes WG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens 1993;11:1375-80
   PubMed Web of Science ®Google Scholar
• Keeble J, al-Swayeh OA, Moore PK. Vasorelaxant effect of nitric oxide releasing steroidal and nonsteroidal anti-inflammatory drugs. Br J Pharmacol 2001;133(7):1023-8
   Google Scholar
• Muscara MN, McKnight W, Lovren F, Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats. Am J Physiol Heart Circ Physiol 2000;279(2):H528-35
   Google Scholar
• Muscara MN, McKnight W, Del SP, Wallace JL. Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Life Sci 1998;62(15):L235-40
   Google Scholar
• White WB, Schnitzer TJ, Fleming R, Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am J Cardiol 2009;104(6):840-5
   Google Scholar
• Piecha D, Weik J, Kheil H, Novel selective MMP-13 inhibitors reduce collagen degradation in bovine articular and human osteoarthritis cartilage explants. Inflamm Res 2009. [Epub ahead of print]
   Google Scholar
• Csaki C, Mobasheri A, Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of interleukin-1beta-induced nuclear factor-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther 2009;11(6):R165
   Google Scholar
• Chia SL, Sawaji Y, Burleigh A, Fibroblast growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS-5 and delays cartilage degradation in murine osteoarthritis. Arthritis Rheum 2009;60(7):2019-27
   Google Scholar